Ezrin-Derived Peptide Sequence Modification for Enhanced Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ezrin-derived peptides, such as HEP-1, have limitations in immunostimulatory activity and antiviral efficacy, necessitating the development of peptides with enhanced immunostimulatory and antiviral properties for treating infections and ulcerative disorders of the gastrointestinal tract.
Innovation Solution
A novel peptide with the amino acid sequence GEKKRRETVEREGG, comprising 14 to 25 residues, is synthesized using non-polar amino acid residues, specifically glycine, alanine, and valine, to achieve higher immunostimulatory and antiviral activity compared to existing peptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HEP-1 peptide is used for treatment, then antiviral and immunostimulatory effects are achieved, but the immunostimulatory activity and antiviral efficacy are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the ezrin-derived peptide. Specifically, the invention uses a peptide with sequence GEKKRRETVEREGG (Formula I) where non-polar amino acid residues (X1, X2, X3) are strategically positioned to enhance immunostimulatory activity. This sequence modification increases the peptide's ability to stimulate immune response and antiviral efficacy compared to the original HEP-1 peptide, directly resolving the contradiction between sufficient immunostimulatory activity and antiviral efficacy.
2Reliability
If peptide sequence is modified to enhance activity, then immunostimulatory and antiviral properties are improved, but peptide structure complexity increases
Solution Approach 1:
The patent applies local quality by making targeted modifications to specific positions in the peptide sequence rather than changing the entire structure. The formula GEKKRRETVEREX1X2X3 specifies that only three positions (X1, X2, X3) require non-polar amino acid residues, while the rest of the sequence remains consistent with the original ezrin-derived peptide structure. This localized modification approach enhances immunostimulatory activity without unnecessarily increasing overall structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel peptide demonstrates significantly higher immunostimulatory and antiviral activity, exceeding that of HEP-1, and is effective in treating viral, bacterial, and fungal infections, as well as ulcerative disorders, by inducing interferon production and activating the MAPK/ERK signaling pathway.
Implementation Method 1
effective in treating viral, bacterial, and fungal infections, as well as ulcerative disorders, by inducing interferon production
Implementation Method 2
activating the MAPK/ERK signaling pathway
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to the field of medicine, specifically, to the field of chemical and pharmaceutical industry and concerns ezrin-derived peptides, in particular, a peptide comprising an amino acid sequence of general formula (I) X1 EKKRRETVERE X2X3, wherein each X represents a non-polar amino acid residue. The use of the peptides as immunostimulatory agents, and more specifically, for use in treating and preventing antiviral, antibacterial and antifungal infections, and treatment of diseases of the GI tract, in particular ulcerative disorders of the GI tract. The present invention also relates to pharmaceutical compositions comprising the peptides. Further, the invention relates to methods of treatment of infection and ulcerative diseases of the GI tract comprising administering the peptides to patients in need thereof.